drugset / Trial / NCT01308606

TMC435-TiDP16-C116 - Relative Bioavailability and Food Effect Study

NCT01308606

Phase 1 Completed 48 enrolled Tibotec Pharmaceuticals, Ireland
RandomizedCrossoverOpen-labelTreatment

Summary

The purpose of this study is to compare absorption of TMC435 formulated as 2 different types of capsules. After that, the absorption of one chosen TMC435 capsule will be compared when taken under fasting conditions or together with a standard or a high-fat meal. This will be done in healthy volunteers.

Timeline

Start
2011-03
Primary completion
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Simeprevir Small molecule 150 mg Oral